Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

i3 Health

Challenges and Opportunities in Hodgkin Lymphoma

Access Activity

Overview / Abstract:


Hodgkin lymphoma (HL) is a rare malignancy involving the lymph nodes and lymphatic system, with 8,500 new cases diagnosed and accounting for 1,050 deaths each year in the United States. In contrast with other cancers whose risk increases with age, the risk for HL increases in patients between 15 and 30 years of age, decreases during middle age, and is followed by another peak in adults older than 55. There are 2 main types of HL: classical HL, which accounts for 95% of cases in Western countries and is characterized by the presence of Reed-Sternberg cells, and nodular lymphocyte-predominant HL, which lacks these cells. The last few decades have seen significant progress in the management of patients with HL, leading to improved outcomes. The 5-year overall survival rate is approximately 90% for early-stage disease. However, challenges remain, such as improving remission rates in patients with advanced disease, who experience 5-year overall survival of approximately 65%, and improving quality of life of survivors, who may be at risk for secondary malignancies and late toxicities.


Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with classical Hodgkin lymphoma (cHL).


Upon completion of this activity, participants should be able to:

1. Describe factors that increase the risk for cHL treatment failure and the development of acute and late toxicities
2. Evaluate emerging data on the treatment of newly diagnosed and relapsed/refractory advanced cHL
3, Assess strategies to manage acute and late toxicities associated with cHL therapy


Jan 20, 2020


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Monograph, Online

Credits / Hours




Presenters / Authors / Faculty

Craig H. Moskowitz, MD (Chairperson)
Professor of Medicine
University of Miami Health Center

Kami Maddocks, MD
Lymphoma Program Director
Ohio State University

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Seattle Genetics.

Keywords / Search Terms

i3 Health i3 Health, Hodgkin lymphoma, HL, hematologic malignancies, lymphoma, oncology, hematology, CE, CME, free CE, free CME, ILNA points Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.